









Markets
/
Stocks
/
nasdaq-ird
/

Opus Genetics Inc

IRD

2.030USD

-0.090-4.25%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

121.61MMarket Cap

LossP/E TTM



Opus Genetics Inc

2.030

-0.090-4.25%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Opus Genetics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Opus Genetics Inc's Score

Industry at a Glance

Industry Ranking

80 / 159

Overall Ranking

206 / 4616

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.286

Target Price

+235.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Opus Genetics Inc Highlights

StrengthsRisks

Opus Genetics, Inc., formerly Ocuphire Pharma, Inc., is a clinical-stage ophthalmic biopharmaceutical company. The Company is engaged in developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. Its pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its most advanced gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and being evaluated in a Phase I/II open-label, dose-escalation trial, with advancing early data. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.99M.

Undervalued

The company’s latest PE is -1.13, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 17.49M shares, decreasing 4.37% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 153.31K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.59.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 8.14, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 2.88M, representing a year-over-year increase of 159.17%, while its net profit experienced a year-over-year increase of 4.44%.

Score

Industry at a Glance

Previous score

8.14

Change



Financials

9.02

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.31

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.16

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Opus Genetics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.93, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -1.13, which is -684.24% below the recent high of 6.58 and -527.08% above the recent low of -7.06.

Score

Industry at a Glance

Previous score

6.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 80/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.29, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Opus Genetics Inc is 8.00, with a high of 9.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

8.29

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

7.286

Target Price

+243.67%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Opus Genetics Inc

IRD

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 7.14, which is higher than the Pharmaceuticals industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 2.38 and the support level at 1.86, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.22

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.019

Neutral

RSI(14)

53.981

Neutral

STOCH(KDJ)(9,3,3)

43.653

Sell

ATR(14)

0.159

High Vlolatility

CCI(14)

-17.791

Neutral

Williams %R

66.667

Sell

TRIX(12,20)

0.698

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.152

Sell

MA10

2.063

Sell

MA20

2.021

Buy

MA50

1.751

Buy

MA100

1.420

Buy

MA200

1.208

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 27.74%, representing a quarter-over-quarter decrease of 39.23%. The largest institutional shareholder is The Vanguard, holding a total of 992.20K shares, representing 1.57% of shares outstanding, with 49.92% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Foundation Fighting Blindness Inc

9.49M

+270.10%

Perceptive Advisors LLC

4.33M

Bios Equity Partners, LP.

3.68M

Nantahala Capital Management, LLC

3.35M

+5.95%

Gallagher (Cam S)

1.81M

+92.42%

Opaleye Management Inc.

1.22M

+3.83%

Mink Brook Asset Management LLC

1.20M

+47.84%

The Vanguard Group, Inc.

Star Investors

992.20K

Bleichroeder LP

736.84K

Magrath (George)

691.31K

+247.13%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.03, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.42. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.